NEW YORK--(BUSINESS WIRE)--Medidata, the global leader in creating end-to-end solutions to support the entire clinical trial process, and a Dassault Systèmes company, announced that Medpace Inc. has entered into an agreement to integrate Medidata Rave Imaging with Medpace's imaging systems and workflow. This will create a seamless platform for capturing, managing, analyzing and storing images and imaging data for clinical trials. Medpace is a leading contract research organization (CRO) with a wholly-owned and fully integrated imaging core lab that offers a suite of global imaging services to enhance and expedite biopharmaceutical and medical device development.

“Medidata is transforming the way the healthcare industry incorporates and leverages imaging in clinical trials,” said Glen de Vries, co-founder and co-CEO, Medidata. “As drug and medical device development depend more on medical imaging, it’s more important than ever to simplify and unify image and data collection. This helps to minimize risk and complexity, and ensures accurate, rapid completion of clinical studies so patients can more quickly benefit from new therapeutics.”

The use and importance of medical imaging in clinical studies continues to grow. Today, over 50 percent of all studies use medical imaging to help determine the efficacy of new drugs and devices and 95 percent when it is an oncology study. Medidata Rave Imaging is an end-to-end cloud-based platform for image management in clinical trials. This includes image capture, advanced edit checks, workflow, form design, electronic data capture (EDC) connection, and intelligent archiving. Medidata processes more than 500 million images annually from nearly 800 studies.
Using Medidata Rave Imaging, Medpace’s imaging core lab will:

Provide Medpace customers with a single, familiar location for site data entry and image uploads
Optimize resources and workflow, reduce manual reconciliation steps, increase data visibility, and create a single data repository on a unified trial platform
Compute quantitative imaging biomarkers for clinical trials in oncology, metabolic disease, and neuroscience
Create an integrated workflow to determine patient eligibility, monitor disease progression or response, and make go / no go clinical decisions that provide customers with a more streamlined and effective approach for managing vital imaging components of their study
“Through our partnership with Medidata, Medpace is now able to provide seamless integration of our quantitative image analysis pipelines with Medidata’s Rave Imaging system and database,” said Daniel O’Leary, MD, chief medical officer for Medpace’s imaging core lab. “The combination of these tools produces the most powerful imaging trial management environment currently available to the clinical trial market.”

Health IT Homepage